Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple MyelomaAurore Perrot, Jill Corre, Marie‐Lorraine Chrétien et al.|Journal of Clinical Oncology|2019Cited by 179
Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 studyMurielle Roussel, Marguerite Vignon, Valérie Lauwers‐Cancès et al.|Blood|2022Cited by 25